Skip to main content

The 5 Most Interesting Analyst Questions From Edgewell Personal Care’s Q2 Earnings Call

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

EPC Cover Image

Edgewell Personal Care's second quarter saw a positive market reaction despite missing Wall Street’s revenue expectations, as management highlighted improved execution in North America and gains across key brands such as Hawaiian Tropic and Cremo. CEO Rod Little attributed the progress to a focused investment behind global brands and the benefits of organizational simplification following the divestiture of the Feminine Care business. The quarter also reflected the initial benefits of a major manufacturing consolidation, although temporary supply chain disruptions weighed on private label and international performance.

Is now the time to buy EPC? Find out in our full research report (it’s free for active Edge members).

Edgewell Personal Care (EPC) Q2 CY2026 Highlights:

  • Revenue: $570.1 million vs analyst estimates of $577.1 million (1.7% year-on-year growth, 1.2% miss)
  • Adjusted EPS: $0.72 vs analyst estimates of $0.61 (17.6% beat)
  • Adjusted EBITDA: $71.6 million vs analyst estimates of $72.89 million (12.6% margin, 1.8% miss)
  • Adjusted EPS guidance for the full year is $1.90 at the midpoint, beating analyst estimates by 0.6%
  • EBITDA guidance for the full year is $255 million at the midpoint, in line with analyst expectations
  • Operating Margin: 4.4%, down from 8% in the same quarter last year
  • Organic Revenue rose 1.1% year on year (miss)
  • Market Capitalization: $1.32 billion

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Edgewell Personal Care’s Q2 Earnings Call

  • Peter Grom (UBS) asked about Edgewell’s confidence in accelerated growth for the fourth quarter despite recent weakness in Wet Shave and international. CEO Rod Little responded that supply disruptions were transitory and that brand momentum and increased advertising would drive improvement.
  • Christopher Carey (Wells Fargo Securities) questioned the sustainability of gross margin gains post-divestiture. CEO Rod Little and CFO Francesca Weissman explained that higher-margin focus and productivity initiatives should yield year-over-year margin expansion, notwithstanding commodity price uncertainty.
  • Christopher Carey (Wells Fargo Securities) also sought clarification on the board’s response to an unsolicited acquisition offer. Little reiterated that the board remains focused on organic value creation but would consider any offer that clearly exceeds the current growth plan.
  • Susan Anderson (Canaccord Genuity) inquired about branded performance in international markets, especially Schick in Japan and Billie in the U.S. Little noted strong innovation and growth in Japan, while Weissman affirmed Billie’s continued share gains and increased household penetration.
  • Olivia Tong Cheang (Raymond James) asked about the broad range implied in Q4 guidance and sales expectations for next year. Little described the range as appropriate for current market volatility and expressed confidence in achieving low single-digit growth, citing stronger distribution and brand health.

Catalysts in Upcoming Quarters

Looking ahead, our analysts will closely track (1) the stabilization and growth of international sales as supply chain issues resolve, (2) the effectiveness of new product launches and brand campaigns—especially for Banana Boat and Billie, and (3) the realization of margin expansion through productivity initiatives and operational simplification. The impact of commodity cost volatility and continued investment in brand innovation will also be critical to monitor.

Edgewell Personal Care currently trades at $28.62, in line with $28.53 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  267.28
+0.00 (0.00%)
AAPL  302.25
+0.00 (0.00%)
AMD  482.93
+0.00 (0.00%)
BAC  64.81
+0.00 (0.00%)
GOOG  342.37
+0.00 (0.00%)
META  578.85
+0.00 (0.00%)
MSFT  492.43
+0.00 (0.00%)
NVDA  224.09
+0.00 (0.00%)
ORCL  153.28
+0.00 (0.00%)
TSLA  327.51
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.